Zollinger‑Ellison syndrome (gastrinoma) – metastatic - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Gastrinoma) – Metastatic

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors—called gastrinomas—develop in the pancreas or duodenum. These tumors secrete excess gastrin, a hormone that stimulates the stomach lining to produce large amounts of acid. When the disease has spread (metastasized) to the liver, lymph nodes, or other organs, it is termed metastatic gastrinoma.

  • Who it affects: ZES can occur at any age but most commonly presents in adults between 30‑60 years. Both men and women are affected, with a slight male predominance (approximately 55 % male).1
  • Prevalence: Gastrinomas are among the rarest functional neuroendocrine tumors, with an estimated incidence of 0.5–2 cases per million people per year. About 20‑25 % of patients with gastrinomas already have metastases at the time of diagnosis.2
  • Association with genetic syndromes: Roughly 25 % of gastrinomas occur in the context of multiple endocrine neoplasia type 1 (MEN 1), an inherited condition that also predisposes patients to tumors of the parathyroid, pituitary, and other pancreatic islet cells.3

Symptoms

The excessive gastric acid in ZES leads to a constellation of gastrointestinal and systemic signs. Metastatic disease may add symptoms related to tumor spread.

  • Peptic ulcer disease (PUD): Multiple, recurrent, or treatment‑resistant ulcers in the stomach, duodenum, or jejunum; ulcers may be larger than 2 cm and can occur beyond the duodenum (e.g., in the ileum).
  • Abdominal pain: Often described as a burning or gnawing pain that improves with meals or antacids.
  • Diarrhea: Occurs in 30‑70 % of patients; may be watery, nocturnal, and sometimes accompanied by steatorrhea due to acid‑induced inactivation of pancreatic enzymes.
  • Heartburn / GERD: Persistent reflux symptoms resistant to over‑the‑counter therapy.
  • Nausea & vomiting: Can result from ulcer perforation or severe acid load.
  • Weight loss: Due to malabsorption, chronic diarrhea, and decreased intake because of pain.
  • Gastrointestinal bleeding: Melena or hematemesis from ulcer erosion.
  • Signs of metastasis:
    • Hepatic involvement – right‑upper‑quadrant fullness, jaundice, or unexplained liver enzyme elevation.
    • Lymph‑node spread – palpable abdominal masses.
    • Bone metastases – bone pain or pathologic fractures (rare).

Causes and Risk Factors

ZES is fundamentally a neuroendocrine tumor driven by genetic and sporadic events.

  • Genetic mutations: Loss‑of‑function mutations in the MEN1 gene (chromosome 11q13) are the most common in hereditary cases. Sporadic gastrinomas often harbor mutations in ATRX, DAXX, and TP53.4
  • Multiple endocrine neoplasia type 1 (MEN 1): Individuals with MEN 1 have a 10‑30 % lifetime risk of developing gastrinomas.
  • Age and sex: Peak incidence in middle age; slight male predominance.
  • Family history: First‑degree relatives with MEN 1 or previously diagnosed gastrinomas increase risk.
  • Environmental factors: No strong links to diet, smoking, or alcohol have been established.

Diagnosis

Because ZES mimics common ulcer disease, a high index of suspicion is required, especially when ulcers are atypical or refractory.

Biochemical testing

  • Fasting serum gastrin: Levels > 1,000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when accompanied by a gastric pH < 2.5
  • Secretin stimulation test: In ZES, gastrin paradoxically rises > 120 pg/mL after IV secretin (0.4 U/kg). This test distinguishes ZES from other causes of hypergastrinemia.
  • Other labs: Serum chromogranin A (elevated in many neuroendocrine tumors), liver function tests, and fasting glucose (MEN 1 patients may have concurrent insulinoma).

Imaging studies

  • Endoscopic ultrasound (EUS): Highly sensitive for small (< 1 cm) pancreatic or duodenal lesions.
  • Multiphasic contrast‑enhanced CT or MRI: Identifies primary tumor and assesses liver, lymph‑node, or distant metastases.
  • Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT: Gold standard for staging neuroendocrine tumors; detects both primary and metastatic disease with > 90 % sensitivity.
  • Selective arterial secretin injection (SASI) test: Rarely used; helps localize occult gastrinomas when non‑invasive imaging is inconclusive.

Pathology

If surgical resection is performed, the specimen is examined for tumor size, depth of invasion, Ki‑67 proliferative index, and mitotic count—factors that determine the WHO grade (G1‑G3) and guide therapy.6

Treatment Options

Management aims to control acid hypersecretion, remove or reduce tumor burden, and address metastatic disease.

Acid‑suppression therapy

  • Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line; doses often 2‑4 times the standard daily amount. PPIs normalize gastric pH, heal ulcers, and improve quality of life.
  • H2‑receptor antagonists: May be added if PPIs alone are insufficient, but rarely required.

Surgical approaches

  • Curative resection: Enucleation or pancreaticoduodenectomy (Whipple) for localized tumors without metastases; long‑term disease‑free survival up to 80 % in selected patients.7
  • Debulking surgery: Removal of > 90 % of tumor burden in metastatic disease can reduce gastrin output and improve symptoms.
  • Liver-directed therapies: Radiofrequency ablation, hepatic artery embolization, or stereotactic body radiotherapy for liver metastases.

Medical therapies for metastatic gastrinoma

  • Somatostatin analogues (SSAs): Octreotide or lanreotide bind somatostatin receptors, decreasing gastrin secretion and tumor growth. Typical dose: octreotide LAR 30 mg IM every 4 weeks.
  • Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for progressive, well‑differentiated pancreatic neuroendocrine tumors.
  • Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers targeted radiation to somatostatin‑receptor‑positive lesions; recent trials show objective response rates of 30‑40 % and symptom control in > 80 % of patients.8
  • Chemotherapy: Reserved for high‑grade (G3) or poorly differentiated tumors; regimens may include temozolomide‑capecitabine or streptozocin‑based protocols.

Lifestyle and supportive care

  • Small, frequent meals that are low in fat and non‑irritating.
  • Avoidance of NSAIDs, aspirin, and alcohol, which can worsen ulcer disease.
  • Bone health monitoring if long‑term SSA or everolimus therapy is used (consider calcium, vitamin D, and DEXA scanning).

Living with Zollinger‑Ellison syndrome (gastrinoma) – metastatic

Managing a chronic, metastatic condition involves daily habits, regular monitoring, and a partnership with your healthcare team.

Medication adherence

  • Take PPIs exactly as prescribed—often 2–3 times daily. Missing doses can precipitate severe ulcer bleeding.
  • Set reminders for long‑acting SSA injections and any oral targeted agents.

Nutrition

  • Meal timing: Eat every 3‑4 hours; include a protein source to buffer acid.
  • Low‑acid foods: Yogurt, oatmeal, bananas, and non‑citrus fruits are generally well tolerated.
  • Hydration: Aim for 2–3 L of water per day unless restricted for other reasons.
  • Supplements: Calcium citrate (better absorbed in acidic environments) and vitamin D 3 to protect bone density.

Monitoring and follow‑up

  • Serum gastrin levels every 3–6 months (or sooner after therapy changes).
  • Imaging (CT/MRI or Ga‑68 DOTATATE PET) every 6–12 months to track tumor size and new metastases.
  • Endoscopy every 1–2 years, or sooner if symptoms worsen.
  • Regular liver function tests and complete blood counts, especially when on everolimus or PRRT.

Psychosocial wellbeing

  • Join support groups (e.g., NET Patient Foundation, ZES-specific forums).
  • Consider counseling or cognitive‑behavioral therapy to cope with chronic illness anxiety.
  • Maintain a physical activity routine—low‑impact walking or swimming 150 minutes per week, as tolerated.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies include:

  • Genetic counseling: Individuals with a family history of MEN 1 should undergo genetic testing. Early detection allows surveillance for gastrinomas before they become symptomatic.
  • Avoid chronic gastric irritants: Long‑term PPI overuse without indication can mask early ulcer disease but does not prevent tumor formation.
  • Regular medical check‑ups: In known MEN 1 carriers, annual fasting gastrin measurement and imaging every 2–3 years are recommended by the NIH consensus guidelines.9

Complications

If left untreated or inadequately controlled, ZES can lead to serious health issues:

  • Refractory peptic ulcer disease – perforation, hemorrhage, and need for emergent surgery.
  • Severe gastro‑intestinal bleeding – may require endoscopic hemostasis, angiographic embolization, or transfusion.
  • Malabsorption and nutritional deficiencies – chronic diarrhea leads to loss of fat‑soluble vitamins (A, D, E, K) and electrolytes.
  • Metastatic progression – liver failure, portal hypertension, or bone pain from skeletal mets.
  • Secondary pancreatic insufficiency – due to acid inactivation of pancreatic enzymes.
  • Psychological distress – chronic pain and medication burden can cause depression or anxiety.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with antacids or PPIs.
  • Vomiting of blood (hematemesis) or material that looks like coffee grounds.
  • Black, tarry stools (melena) indicating upper‑GI bleeding.
  • Signs of perforated ulcer: sudden sharp pain, abdominal rigidity, fever, or rapid heart rate.
  • Profuse, watery diarrhea leading to dehydration (dry mouth, dizziness, weak pulse).
  • New onset jaundice, itching, or right‑upper‑quadrant swelling suggesting liver involvement.
  • Severe weakness, confusion, or fainting, which may signal massive blood loss or electrolyte imbalance.

References:

  1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
  2. American Cancer Society. “Pancreatic Neuroendocrine Tumors.” 2022. https://www.cancer.org
  3. NIH Genetic and Rare Diseases Information Center. “Multiple endocrine neoplasia type 1.” 2021.
  4. Jiao Y, et al. “Frequent mutations of DAXX/ATRX, MEN1 and mTOR pathway genes in pancreatic neuroendocrine tumors.” Nat Genet. 2011.
  5. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison syndrome.” 2022.
  6. World Health Organization. “Classification of endocrine and neuroendocrine tumours.” 2020.
  7. O’Dorisio TM, et al. “Surgical outcomes for gastrinomas.” Ann Surg. 2019.
  8. Strosberg J, et al. “Phase 3 Trial of ^177Lu-DOTATATE for Midgut Neuroendocrine Tumors.” N Engl J Med. 2017.
  9. National Institutes of Health Consensus Statement on MEN 1. 2012.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References